(Q52553056)

3 May 2018

title

Induction of EAE in mice with recombinant human MOG, and treatment of EAE with a MOG peptide. (English)

1 reference

3 May 2018

author name string

Devaux B

1

1 reference

3 May 2018

Enderlin F

2

1 reference

3 May 2018

Wallner B

3

1 reference

3 May 2018

Smilek DE

4

1 reference

3 May 2018

publication date

1 May 1997

1 reference

3 May 2018

Journal of Neuroimmunology

published in

1 reference

3 May 2018

volume

75

1 reference

3 May 2018

issue

1-2

1 reference

3 May 2018

page(s)

169-173

1 reference

3 May 2018

Purification and partial structural and functional characterization of mouse myelin/oligodendrocyte glycoprotein

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2897%2900019-2

7 January 2021

Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2897%2900019-2

7 January 2021

T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2897%2900019-2

7 January 2021

Myelin/oligodendrocyte glycoprotein is a unique member of the immunoglobulin superfamily.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2897%2900019-2

7 January 2021

Amelioration of Autoimmune Encephalomyelitis by Myelin Basic Protein Synthetic Peptide-Induced Anergy

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2897%2900019-2

7 January 2021

Reversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of interferon gamma and tumor necrosis factor alpha production

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2897%2900019-2

7 January 2021

Chronic relapsing experimental autoimmune encephalomyelitis with a delayed onset and an atypical clinical course, induced in PL/J mice by myelin oligodendrocyte glycoprotein (MOG)-derived peptide: preliminary analysis of MOG T cell epitopes

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2897%2900019-2

7 January 2021

A novel myelin-associated glycoprotein defined by a mouse monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2897%2900019-2

7 January 2021

T cells specific for the myelin oligodendrocyte glycoprotein mediate an unusual autoimmune inflammatory response in the central nervous system.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2897%2900019-2

7 January 2021

Immunological aspects of demyelinating diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2897%2900019-2

7 January 2021

Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2897%2900019-2

7 January 2021

A myelin oligodendrocyte glycoprotein peptide induces typical chronic experimental autoimmune encephalomyelitis in H-2b mice: fine specificity and T cell receptor V beta expression of encephalitogenic T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2897%2900019-2

7 January 2021

Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: influence of MHC binding affinity

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2897%2900019-2

7 January 2021

A single amino acid change in a myelin basic protein peptide confers the capacity to prevent rather than induce experimental autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2897%2900019-2

7 January 2021

Antigen recognition in autoimmune encephalomyelitis and the potential for peptide-mediated immunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2897%2900019-2

7 January 2021

The T lymphocyte in experimental allergic encephalomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2897%2900019-2

7 January 2021

10.1016/S0165-5728(97)00019-2

Identifiers

DOI

1 reference

3 May 2018

1 reference

3 May 2018